FDA allows imports of syphilis drug alternate during shortage
时间:2024-06-02 02:05:55 阅读(143)
US regulators gave temporary permission for importation of a form of penicillin used to treat syphilis amid a national shortage of Pfizer Inc.’s version of the drug along with a dramatic increase in cases.
The Food and Drug Administration authorized importation of penicillin G benzathine made by a French company, Laboratoires Delbert, according to the agency website. Pfizer’s Bicillin L-A, the only version of the drug available in the US, has been in short supply since April.
While as little as one injection of penicillin G benzathine can cure syphilis, the shortage prompted US health officials to recommend giving some patients doxycycline, another antibiotic therapy that requires of weeks of twice-daily pills. The long treatment regimen raises the risk that patients might not complete it, leaving them sick and potentially infectious to others.
The National Coalition of STD Directors applauded the FDA’s action. “We hope this is the first step toward seeing a resolution to this shortage,” David Harvey, executive director of NCSD, said in a statement. Harvey had previously criticized the federal government’s response.
To fix the shortage, Pfizer has added manufacturing shifts and more than halved production time. The company has invited customers who are having trouble getting the drug to contact them directly. “We continue to supply the market above historical rates, and we are reserving product for emergency needs,” a Pfizer spokesperson said.
The shortage is estimated to last through June, according to the FDA.
Unlike Pfizer’s prefilled syringe, Laboratoires Delbert’s formulation of the drug is a powder that must be mixed and then injected by a health-care provider.
猜你喜欢
- Rising oil supply could lead to tough time for traders, all eyes on OPEC and allies for support
- Stocks To Watch- Hero MotoCorp, Vedanta, Adani Enterprises, Indigo, JSW Steel, Ambuja Cements, Bharti Airtel
- Global stocks higher on hopes US rate hike plans will ease
- Rupee gains 30 paise to close at 81
- Gold outlook- No clear direction ahead of FOMC; wait for breakout above 51400 or below 50000 before buying
- Gold may offer 7% returns from current levels; Russia-Ukraine war, inflation, Fed tightening among key factors
- Rupee gains 6 paise to end at 82
- Stocks To Watch- RIL, LTIMindtree, Indian Oil, Adani Total Gas, Infosys, Patanjali Foods, Central Bank of India
- Rupee falls 27 paise to 82